Fluzoparib and Camrelizumab in Treating Patients With R/M NPC That Progressed After First-line Chemotherapy
NCT04978012
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
48
Enrollment
OTHER
Sponsor class
Conditions
Nasopharyngeal Carcinoma
Nasopharyngeal Cancer
Interventions
DRUG:
Fluzoparib and Camrelizumab
Sponsor
Fudan University